Researchers sought to determine whether patient groups are accurately represented in clinical trials leading to the approval of drugs for patients with leukemia or MM.
Researchers sought to evaluate cognitive function in patients with hematologic cancers and the feasibility conducting cognitive assessments remotely in these patients.
Researchers sought to determine whether there was a connection between loss of the 2q37 chromosomal region and resistance to immunomodulatory drugs in MM.
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers.
Multiple myeloma patients age 75 and older present with more advanced disease and have worse outcomes in the real world than in clinical trials, a study suggests.
Researchers sought to determine whether ciltacabtagene autoleucel would result in durable responses in patients with R/R multiple myeloma.
Researchers sought to determine whether hypoxia would induce chemoresistance to proteasome inhibitors in patients with multiple myeloma.
The approval was based on data from the MajesTEC-1 study which included 110 adults with relapsed or refractory multiple myeloma who had previously received ≥3 prior therapies.
